Table 4.
Characteristics | Univariate | Multivariate | ||
---|---|---|---|---|
p-Value | HR | 95%CI | p-Value | |
Age (>50 vs ≤50) | 0.069 | 0.485 | 0.237–0.989 | 0.047 |
Menopausal status (pre vs post) | 0.765 | |||
Surgery (mastectomy vs BCS) | 0.334 | |||
Pathology (IDC vs others) | 0.799 | |||
Tumors (≤2 cm vs >2 cm) | 0.252 | 1.365 | 0.643–2.897 | 0.417 |
Nodes involved (negative vs positive) | 0.013 | 2.866 | 1.371–5.992 | 0.005 |
Grade (I-II vs III) | 0.848 | |||
ER (positive vs negative) | 0.557 | 0.725 | 0.351–1.495 | 0.383 |
PR (positive vs negative) | 0.591 | 0.837 | 0.276–2.543 | 0.754 |
Ki67 (≤30% vs >30%) | 0.013 | 0.404 | 0.185–0.885 | 0.023 |
Chemotherapy (EC-T vs others) | 0.721 | |||
Radiation (yes vs no) | 0.323 | |||
Endocrine therapy (yes vs no) | 0.910 | |||
ALC (≥1.8 vs <1.8) | 0.014 | 2.723 | 1.211–6.122 | 0.015 |
NLR (≥1.77 vs<1.77) | 0.047 | 0.619 | 0.275–1.394 | 0.247 |
ANC (≥3.2 vs <3.2) | 0.645 |
Abbreviations: IDC, invasive ductal carcinoma; BCS, breast conserving surgery; ER, estrogen receptor; PR, progestrone receptor; ANC, absolute neutrophil count; ALC, absolute lymphocyte count; NLR, neutrophil to lymphocyte ratio.